Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C

Clin Infect Dis (2017) 64 (11): 1615-1618.

DOI:

https://doi.org/10.1093/cid/cix214

Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C

Christophe Hézode Slim Fourati Stéphane Chevaliez Giovanna Scoazec Alexandre Soulier Anne Varaut Murielle François Isaac Ruiz Françoise Roudot-Thoraval Ariane Mallat Jean-Michel Pawlotsky

Abstract

We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral–experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks’ treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.

View Article
PDF Download

Full Text Article
Article link provided by Henry E. Chang.

I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading full text articles about the treatment and management of hepatitis C.